Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease

BACKGROUND: The ability of unstandardized methods to track kidney growth in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) has not been critically evaluated. METHODS: The Tolvaptan Efficacy and Safety Management of ADPKD and its Outcomes (TEMPO) 3:4 study involved baseline...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Kidney J
Hlavní autoři: Edwards, Marie E, Blais, Jaime D, Czerwiec, Frank S, Erickson, Bradley J, Torres, Vicente E, Kline, Timothy L
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Familial Nephropathies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366146/
https://ncbi.nlm.nih.gov/pubmed/30746130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy078
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky